Novo Nordisk said on Tuesday it will stop a trial studying Ozempic to treat kidney failure in diabetes patients ahead of schedule because it was clear from an interim analysis that the treatment would succeed. Novo said the trial would be halted almost a year early based on...
Novo Nordisk said on Tuesday it will stop a trial studying Ozempic to treat kidney failure in diabetes patients ahead of schedule because it was clear from an interim analysis that the treatment would succeed.
Novo said the trial would be halted almost a year early based on a recommendation from the independent data monitoring board overseeing the study. Independent monitors can recommend stopping a trial early if there is clear evidence that a drug was going to succeed or fail based on interim analyzes.
Since the start of the year, Novo has been riding a wave of demand for its highly effective semaglutide-based diabetes and weight-loss drugs that transformed the drugmaker into a $315 billion powerhouse. The company briefly unseated luxury goods brand LVMH as Europe's most valuable listed company in September, and has seen its shares rise by around 17% since it announced in August that a large study had shown Wegovy had clear cardiovascular benefits.
Novo's success has also created an economic boom for Denmark, according to Danish economists, analysts, and executives at the Novo Nordisk Foundation.
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Novo Nordisk stops Ozempic kidney trial after early signs of successNovo Nordisk (NOVOb.CO) said on Tuesday it will stop a trial studying Ozempic to treat kidney failure in diabetes patients ahead of schedule because it was clear from an interim analysis that the treatment would succeed.
Read more »
Dialysis company shares plunge after Ozempic trial success vs. kidney troubleSteven Goldstein is based in London and responsible for MarketWatch's coverage of financial markets in Europe, with a particular focus on global macro and commodities. Previously, he was Washington bureau chief, directing MarketWatch's economic, political and regulatory coverage. Follow Steve on Twitter: MKTWgoldstein.
Read more »
Novo Nordisk, Eli Lilly leap as Ozempic show promise in kidney patient treatmentOzempic, the diabetes treatment often prescribed for weight loss, is also proving highly-effective in treating patients with chronic kidney disease.
Read more »
Stocks edge higher, 10-year auction on deck, Ozempic trial success, Exxon-Pioneer takeover, Delta Air...Stocks higher, 10-year auction, Ozempic, Exxon-Pioneer, Delta Air Lines
Read more »
How Ozempic and Wegovy turned Novo Nordisk into a $400 billion companyHow Ozempic and Wegovy turned Novo Nordisk into a $400 billion company
Read more »
Novo Nordisk Halts Ozempic Kidney Trial. Why It's Bad for DaVita Stock.Novo Nordisk’s Ozempic already is poised to disrupt a range of industries via its weight-loss benefits. Now it threatens companies which treat kidney failure.
Read more »